Riskpilot← Back to searchSign inGet full accessFridsbo Pharma AB
ABActiveOrg 5590570338Norrevångsvägen 56Research and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2025
SEK 0
EBITDA margin
—
-87% vs 2024
Equity ratio
93.4%
Financial strength
Net profit 2025
SEK -2K
-112% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -37K | -87% |
| Net profit | SEK -2K | -112% |
| Total assets | SEK 1,9M | -1% |
| Equity | SEK 1,8M | +0% |
| Employees | 0 | — |
Legal name
Fridsbo Pharma AB
Org number
5590570338
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 april 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva konsultverksamhet innefattande företagsledning, affärsutveckling och administrativ service till företag inom läkemedel, bioteknik, medicinisk teknik, diagnostik och därmed förenlig verksamhet.
Address
Norrevångsvägen 56
Email
mats.persson@privat.utfors.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 751 | 890 | −0 | 0 | 0 |
| Staff expenses | — | −425 | −786 | −0 | −0 |
| EBITDA | 2 059 | 190 | −694 | −20 | −37 |
| Depreciation & amort. | −13 | −153 | — | — | — |
| EBIT | 2 046 | 37 | −694 | −20 | −37 |
| Net financials | — | −0 | 26 | 51 | 25 |
| Profit before tax | 1 372 | 29 | −0 | 23 | −2 |
| Tax | −283 | −7 | −2 | −5 | — |
| Net profit | 1 089 | 22 | −2 | 18 | −2 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 334 | 3 358 | 1 997 | 1 931 | 1 915 |
| Equity | 1 753 | 1 775 | 1 773 | 1 791 | 1 789 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 810 | 804 | 116 | 25 | 20 |
| Total debt | 810 | 804 | 116 | 25 | 20 |
EBITDA margin
-3659900.0%
This company
15.8%
Market median
-23164024% vs market
20212025
Equity ratio
93.4%
This company
38.2%
Market median
+145% vs market
20212025
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20212025
Net profit margin
-214700.0%
This company
8.1%
Market median
-2650717% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fridsbo Holding AB
Fridsbo Pharma AB Board members of Fridsbo Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ingrid Elisabet Persson | Deputy Board Member | 0 companies |
| Mats Otto Persson | Board of Directors | 0 companies |